| Record Information |
|---|
| Version | 1.0 |
|---|
| Creation Date | 2009-03-06 18:58:07 UTC |
|---|
| Update Date | 2016-11-09 01:08:10 UTC |
|---|
| Accession Number | CHEM000111 |
|---|
| Identification |
|---|
| Common Name | Plutonium-239 |
|---|
| Class | Small Molecule |
|---|
| Description | Plutonium is an element with the symbol Pu and atomic number 94. It is a rare transuranic radioactive element that normally exhibits six allotropes and four oxidation states. It is also a radioactive poison that accumulates in bone marrow. Plutonium-239 is the most important isotope of plutonium, with a half-life of 24,100 years. It is fissile and can therefore sustain a nuclear chain reaction, leading to applications in nuclear weapons and nuclear reactors. Pu-239 is synthesized by irradiating uranium-238 with neutrons in a nuclear reactor, then recovered via nuclear reprocessing of the fuel. (3) |
|---|
| Contaminant Sources | - IARC Carcinogens Group 1
- T3DB toxins
|
|---|
| Contaminant Type | - Industrial/Workplace Toxin
- Inorganic Compound
- Metal
- Natural Compound
- Plutonium Compound
- Pollutant
- Radioactive
- Radioactive Isotope
|
|---|
| Chemical Structure | |
|---|
| Synonyms | | Value | Source |
|---|
| 239Pu radioisotope | MeSH | | Pu-239 radioisotope | MeSH |
|
|---|
| Chemical Formula | Pu |
|---|
| Average Molecular Mass | 239.052 g/mol |
|---|
| Monoisotopic Mass | 239.052 g/mol |
|---|
| CAS Registry Number | 15117-48-3 |
|---|
| IUPAC Name | (²³⁹Pu)plutonium |
|---|
| Traditional Name | (²³⁹Pu)plutonium |
|---|
| SMILES | [239Pu] |
|---|
| InChI Identifier | InChI=1S/Pu/i1-5 |
|---|
| InChI Key | OYEHPCDNVJXUIW-FTXFMUIASA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | belongs to the class of inorganic compounds known as homogeneous actinide compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a transition metal atom. |
|---|
| Kingdom | Inorganic compounds |
|---|
| Super Class | Homogeneous metal compounds |
|---|
| Class | Homogeneous actinide compounds |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Homogeneous actinide compounds |
|---|
| Alternative Parents | Not Available |
|---|
| Substituents | |
|---|
| Molecular Framework | Not Available |
|---|
| External Descriptors | Not Available |
|---|
| Biological Properties |
|---|
| Status | Detected and Not Quantified |
|---|
| Origin | Exogenous |
|---|
| Cellular Locations | |
|---|
| Biofluid Locations | Not Available |
|---|
| Tissue Locations | Not Available |
|---|
| Pathways | Not Available |
|---|
| Applications | Not Available |
|---|
| Biological Roles | Not Available |
|---|
| Chemical Roles | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Appearance | Not Available |
|---|
| Experimental Properties | | Property | Value |
|---|
| Melting Point | Not Available | | Boiling Point | Not Available | | Solubility | Not Available |
|
|---|
| Predicted Properties | |
|---|
| Spectra |
|---|
| Spectra | | Spectrum Type | Description | Splash Key | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-000i-0090000000-3e228917de618e678df1 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-000i-0090000000-3e228917de618e678df1 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-000i-0090000000-3e228917de618e678df1 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-000i-0090000000-7d39ee3442df3fef5b77 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-000i-0090000000-7d39ee3442df3fef5b77 | Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-000i-0090000000-7d39ee3442df3fef5b77 | Spectrum |
|
|---|
| Toxicity Profile |
|---|
| Route of Exposure | Oral (6) ; Inhalation (6) |
|---|
| Mechanism of Toxicity | The alpha radiation plutonium emits does not penetrate the skin but can irradiate internal organs when plutonium is inhaled or ingested. Particularly at risk are the skeleton, where it is likely to be absorbed by the bone surface, and the liver, where it collects and becomes concentrated. The ionizing radiation produced by plutonium causes cellular damage that includes DNA breakage, accurate or inaccurate repair, apoptosis, gene mutations, chromosomal change, and genetic instability. This leads to loss of normal cell and tissue homeostasis, and development of malignancy. Ionizing radiation that does not directly damage DNA can produce reactive oxygen intermediates that directly affect the stability of p53, an important enzyme in cell-cycle regulation, and produce oxidative damage to individual bases in DNA and point mutations by mispairing during DNA replication. (2, 4) |
|---|
| Metabolism | Plutonium-238 can affect the body following ingestion or inhalation. When inhaled, Pu-239 tends to accumulate in the lungs, though it also distributes to the liver and skeleton. Ingested plutonium is found in the liver and bone. Plutonium metabolism consists primarily of hydrolytic reactions and formation of complexes with protein and nonprotein ligands, such as albumin, globulins, ferritin, citrate, and lactate. Plutonium is excreted in feces and urine. (4) |
|---|
| Toxicity Values | Not Available |
|---|
| Lethal Dose | Not Available |
|---|
| Carcinogenicity (IARC Classification) | 1, carcinogenic to humans. (1) |
|---|
| Uses/Sources | Plutonium-239 is a key fissile component in nuclear weapons, due to its ease of fission and availability. (3) |
|---|
| Minimum Risk Level | Not Available |
|---|
| Health Effects | Plutonium's radioactivity can cause cancers of the bone, liver, and lungs if ingested or inhaled. Large amounts may also cause acute radiation poisoning. (3, 4) |
|---|
| Symptoms | Exposure to high doses of ionizing radiation results in acute radiation syndrome, which can cause skin burns, hair loss, nausea, vomiting, dizziness, disorientation, low blood pressure, headache, fatigue, weakness, fever, birth defects, illness, infection, and death. (2, 5) |
|---|
| Treatment | Treatment reversing the effects of irradiation is currently not possible. Anaesthetics and antiemetics are administered to counter the symptoms of exposure, as well as antibiotics for countering secondary infections due to the resulting immune system deficiency. (5) |
|---|
| Concentrations |
|---|
| Not Available |
|---|
| External Links |
|---|
| DrugBank ID | Not Available |
|---|
| HMDB ID | Not Available |
|---|
| FooDB ID | Not Available |
|---|
| Phenol Explorer ID | Not Available |
|---|
| KNApSAcK ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| BioCyc ID | Not Available |
|---|
| METLIN ID | Not Available |
|---|
| PDB ID | Not Available |
|---|
| Wikipedia Link | Plutonium-239 |
|---|
| Chemspider ID | Not Available |
|---|
| ChEBI ID | Not Available |
|---|
| PubChem Compound ID | 61782 |
|---|
| Kegg Compound ID | Not Available |
|---|
| YMDB ID | Not Available |
|---|
| ECMDB ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Not Available |
|---|
| MSDS | Not Available |
|---|
| General References | Not Available |
|---|
